FifthAmendment to Master Service Agreement, dated February 1, 2022, by and between the Registrant and inVentiv Commercial Services, LLC

Exhibit 10-5

​

Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant customarily and actually treats as private and confidential.

​

FIFTH AMENDMENT TO PROJECT AGREEMENT (DETAILING – FIELD TEAM)

​

This Fifth Amendment (the “Amendment”) entered into as of the last date of signature herein and made effective as of February 1, 2022 (the “Amendment Effective Date”) is made by and between Syneos Health Commercial Services, LLC, f/k/a inVentiv Commercial Services LLC, with an office at 500 Atrium Drive, Somerset, N.J. 08873 (“Syneos Health”) and Agile Therapeutics, Inc. with an office located at 500 College Road East, Suite 310, Princeton, New Jersey 08540 (the “Client”). Syneos Health and Client may each be referred to herein as a “Party” and, collectively, as the “Parties.”

​

W I T N E S S E T H:

​

WHEREAS, Syneos Health and Client are parties to a Project Agreement (Detailing – Field Team) made as of April 30, 2020, First Amendment to Project Agreement (Detailing – Field Team) dated June 1, 2020, Second Amendment to Project Agreement (Detailing – Field Team) dated January 1, 2021, Third Amendment to Project Agreement (Detailing – Field Team) dated July 1, 2021 and Fourth Amendment to Project Agreement dated September 1, 2021 (collectively, the “Agreement”); and

​

WHEREAS, Syneos Health and Client desire to amend the Agreement as set forth

herein.

​

NOW THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, it is agreed as follows:

​

​

​

​

​

Syneos Health will provide Client with a field force that shall consist of up to [***] sales representatives (the “Representatives”) and [***] engagement center representatives (the “EC Reps” and collectively with the Representatives, the “Syneos Health Sales Representatives” or “Sales Representatives”). The Sales Representatives shall detail the Client’s Product by making calls pursuant to a Call Plan on Targets. The Sales Representatives will be managed by up to [***] regional sales managers (the “RSMs”) who will also be Syneos Health employees. Syneos shall also provide [***]allocated at [***]alliance lead (the “Alliance Lead”) and [***] sales trainer manager (the “STM”). The Sales Representatives, RSMs, Alliance Lead and STM may be referred to collectively herein as the “Project Team”.

​

For purposes of clarity, the [***]and [***]outlined in Section I(a) and (b) of Exhibit F includes the headcount for the Project Team as set forth in the table below.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

[***]

[***]

​

-[***]

​

​

​

​

​

​

​

​

​

​

​

​

WHEREFORE, the parties hereto have caused this Amendment to be executed by their duly authorized representatives.

​

AGILE THERAPEUTICS, INC.SYNEOS HEALTH COMMERCIAL

/s/ Al Altomari​ ​By: /s/ Todd Tomasoski​ ​

​

Name:Name:

​

Title: Title:

​

Date: 3/17/2022Date: 3/21/2022